Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
600329
Classement en actions
#4374
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its... Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
Prix de l'action
$6.17
Capitalisation boursière
$3.52B
Changement (1 jour)
-0.05%
Changement (1 an)
-1.86%
Pays
CN
Échange Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
Catégorie
Healthcare
Bénéfices pour Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited de 2001 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2025 | $355.53M | 0.63% |
| 2024 | $353.30M | 128.32% |
| 2023 | $154.74M | 8.90% |
| 2022 | $142.10M | 3.48% |
| 2021 | $137.32M | 16.80% |
| 2020 | $117.57M | 10.16% |
| 2019 | $106.72M | 14.59% |
| 2018 | $93.13M | 14.11% |
| 2017 | $81.61M | 21.49% |
| 2016 | $67.18M | -18.79% |
| 2015 | $82.72M | 18.91% |
| 2014 | $69.56M | 1.17% |
| 2013 | $68.76M | -17.14% |
| 2012 | $82.98M | 85.74% |
| 2011 | $44.67M | -16.41% |
| 2010 | $53.45M | 42.73% |
| 2009 | $37.45M | 56.81% |
| 2008 | $23.88M | -711.08% |
| 2007 | $-3.91M | -92.20% |
| 2006 | $-50.07M | -485.02% |
| 2005 | $13.00M | 15.50% |
| 2004 | $11.26M | -23.83% |
| 2003 | $14.78M | 20.06% |
| 2002 | $12.31M | 20.70% |
| 2001 | $10.20M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
